El interés en corto de Arcus Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Arcus Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Arcus Biosciences (NYSE:RCUS) Bolsa, Informe de interés en corto

Arcus Biosciences

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

Arcus Biosciences Inc

Palantir Technologies Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) shares are in the spotlight Monday ahead of earnings after the bell. Here&#8217;s a look at what <a href="https://www.benzinga.com/top-stories/25/02/43432917/palantir-q4-earnings-countdown-bullish-charts-vs-bearish-analysts">you need to know</a>.
What To Know: Palantir is due to report fourth-quarter financial results after the market close on Monday. The company is expected to report earnings of 11 cents per share and revenue of $775.91 million, according to estimates from&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Palantir shares rallied more than 300% in 2024, driven by the company&#8217;s positioning in the AI space. The stock has nearly doubled since the company reported third-quarter results showing that revenue jumped 30% year-over-year on continued strength in the U.S. The company's customer count also grew 39% after Palantir closed 104 deals worth over $1 million during the period on the back of&nbsp;"unrelenting" AI demand.&nbsp;
"The growth of our business is accelerating, and our financial performance is exceeding expectations as we meet an unwavering demand for the most advanced artificial intelligence technologies from our U.S. government and commercial customers,&#8221;&nbsp;Palantir CEO&nbsp;Alex Karp&nbsp;said in a letter to shareholders last quarter.
Palantir shares bounced back from a selloff last week as investors feared Chinese startup DeepSeek could challenge America's AI leadership position. The company reportedly developed its open-source LLM in a couple of months at a much lower cost than competitors. DeepSeek&#8217;s AI Assistant app also overtook&nbsp;OpenAI&#8217;s ChatGPT&nbsp;as the top-rated free app in Apple&#8217;s App Store last week. 
In a CNBC <a href="https://www.cnbc.com/2025/01/31/palantir-ceo-says-chinas-deepseek-shows-need-for-all-country-effort.html">interview</a> on Friday, Karp indicated that the DeepSeek news shows that the U.S. needs to develop advanced AI at a faster pace, although he suggested that the cost estimates surrounding the development of DeepSeek are likely inaccurate. 
Check This Out: <a href="https://www.benzinga.com/top-stories/25/02/43432917/palantir-q4-earnings-countdown-bullish-charts-vs-bearish-analysts">Palantir Q4 Earnings Countdown: Bullish Charts Vs. Bearish Analysts</a>
PLTR Price Action: <a href="http://benzinga.com/quote/pltr">Palantir shares</a> were down 4.05% at $79.15 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Earnings

News

Previews

Movers

PLTR

What's Going On With Palantir Stock Monday?

IDEXX Laboratories&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDXX#NASDAQ">IDXX</a>) reported fourth-quarter adjusted EPS of $2.53, up 10% year-over-year,&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">beating the consensus of $2.40</a>.
The pet healthcare company reported sales of $954.3 million, beating the consensus of $934.99 million, up 6% on a reported and organic basis in the fourth quarter, driven by Companion Animal Group (CAG) growth of 6% as reported and organically <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43429537/idexx-laboratories-announces-fourth-quarter-and-full-year-2024-results" rel="noreferrer noopener">to $870.47 million</a>.
CAG Diagnostics recurring revenue gains of 6% reported and 7% organic in the quarter were supported by continued benefits from IDEXX execution drivers, including high-quality placements of CAG Diagnostics capital instruments across regions, high customer retention, new business gains, and net price realization.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42638844/large-biopharma-lags-market-jp-morgans-2025-outlook-on-eli-lilly-merck-and-more" rel="noreferrer noopener">Big Biopharma Trails Behind The Market: JP Morgan&#8217;s 2025 Outlook on Eli Lilly, Merck, and More</a>
Water achieved revenue growth of 8% on a reported basis and 9% on an organic basis to $45.15 million, reflecting benefits from net price improvement and solid gains in the U.S. and Europe.
Livestock, Poultry, and Dairy revenue grew 5% on a reported basis and 7% on an organic basis to $34.56 million, supported by solid gains across the U.S., Europe, and Latin America regions.
Gross margins of 59.8% expanded 140 basis points compared to the prior year on a reported basis and expanded 130 basis points on a comparable basis. Gross margin results reflect benefits from net price improvement, which offset inflationary cost impacts, favorable business mix benefits from strong consumable growth, and higher Water gross margins.
Operating margin was 27.4% in the quarter, 20 basis points higher than the prior year period results on a reported basis and 50 basis points higher on a comparable basis.
Guidance: IDEXX Laboratories provides an initial outlook for 2025 revenue of $4.055 billion—$4.170 billion versus a consensus of $4.14 billion, reflecting growth of 4%—7% reported and 6%—9% organic. This is supported by CAG Diagnostics recurring revenue growth of 3%—6% as reported and <a href="https://www.benzinga.com/calendars/guidance">5%—8% on an organic basis.</a>
Estimates 2025 EPS of $11.74&nbsp;&#8211;&nbsp;$12.24 versus consensus of $11.92, an increase of 10% &#8211; 15% as reported and 8% to 12% on a comparable basis.
Outlook assumes ~$1.5 billion of share repurchases in 2025, subject to market conditions, equivalent to ~4% of current equity market capitalization.
Price Action: IDXX stock is up 11.2% at $469.21 at last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/02/43432806/tyson-foods-posts-q1-earnings-protein-conscious-customers-drive-demand-ceo-calls-it-best-quarter-in-2-years" target="_blank" rel="noreferrer noopener">Tyson Foods Posts Q1 Earnings: Protein Conscious Customers Drive Demand, CEO Calls It Best Quarter In 2 Years</a></li>
</ul>
Photo via Shutterstock.

Guidance

Health Care

Trading Ideas

General

IDXX

Why Is Pet Health Company IDEXX Laboratories Stock Trading Higher On Monday?

Scotiabank analyst Phil Hardie maintains Brookfield Bus Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBU#NYSE">BBU</a>) with a Sector Outperform and raises the price target from $32 to $33.

Price Target

Analyst Ratings

Scotiabank Maintains Sector Outperform on Brookfield Bus Partners, Raises Price Target to $33

Scotiabank analyst Mario Saric maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Sector Outperform and raises the price target from $59.5 to $63.

Scotiabank Maintains Sector Outperform on Brookfield Asset Mgmt, Raises Price Target to $63

Scotiabank analyst Eric Winmill maintains Arizona Sonoran Copper (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ASCU#TSX">ASCU</a>) with a Sector Outperform and raises the price target from C$3.25 to C$3.5.

TSX:ASCU

Scotiabank Maintains Sector Outperform on Arizona Sonoran Copper, Raises Price Target to C$3.5

WIIM

SCCO

VALE

Shares of metals stocks are trading lower following US tariffs on Mexico, Canada and China.

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
The SPY is hovering around 593.73. For bullish momentum, we&#8217;d like to see a breakout towards 595.14. Holding above this level could pave the way for buyers to target 596.57. Sustained strength above 596.57 during regular hours may drive the price toward 598.04, with our top bullish target set at 599.24.
If 593.73 fails to act as support, bears will likely challenge 592.00. A breakdown here could trigger a move towards 589.71. If heavy selling persists, the next strong support is at 587.31, with an aggressive downside target of 585.75 if the session turns sharply bearish.
Invesco QQQ Trust Series 1 (QQQ)
The QQQ is trading around 513.64. Bulls need to maintain control above this key level to aim for 515.00. A solid hold could propel the price to 516.58. Continued buying strength may lead to a test of 517.97, with the high bull target positioned at 519.87.
If buyers can&#8217;t sustain 513.64, bears might seize control, pushing the price down to 511.53. Further weakness could see a decline towards 509.87. Persistent selling could drag the price to 508.22, with the low bear target set at 506.68 for the day.
Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)
Apple is positioned near 231.76. Bulls will aim to defend this support level, seeking an upward move to 233.28. If buying pressure holds, the price could advance to 234.20. A strong bullish session might push the price towards our high bull target at 234.97.
Failure to hold 231.76 could see bears testing support at 230.25. Continued selling pressure may drive the price down to 229.03. If sellers remain dominant, the next level to watch is 227.82, with a potential drop to the low bear target of 226.90.
Microsoft Corp. (MSFT)
Microsoft is trading around 409.69. Bulls are looking to secure this level, targeting a move up to 410.64. Sustained buying above this support could lift the price towards 411.72, with further momentum potentially reaching our high bull target at 413.14.
If 409.69 can&#8217;t hold, sellers may push the price down to 408.46. A break below this could open the door to 407.11. Continued downside pressure may target 406.01, with the low bear target set at 404.92.
NVIDIA Corporation (NVDA) NVIDIA is trading near 115.15. Bulls will aim to push the price to 115.83 and establish it as support. A strong buying trend could drive the price up to 116.61, with extended momentum reaching 117.86. The high bull target is 119.44.
If 115.15 fails as support, bears will likely test 114.29. A breakdown here could lead to 113.68. Should selling pressure continue, the price may drop to 112.54, with the low bear target at 111.70.
Alphabet Inc Class A (GOOGL)
Alphabet is trading around 199.96. Bulls will aim to secure 201.28 as support, targeting an upward move to 202.52. Continued bullish momentum could drive the price towards the high bull target at 203.47.
If 199.96 doesn&#8217;t hold, bears may push the price down to 198.87. A break below this could lead to 197.79, and with heavy selling, we could see a drop to the low bear target at 196.97.
Meta Platforms Inc (META)
Meta is positioned around 676.46. Bulls will look to maintain this level as support, targeting a move to 679.79. Strong buying could propel the price to 683.97, with continued momentum potentially reaching the high bull target of 689.09.
If 676.46 fails as support, bears may drive the price down to 671.80. Further selling could push it to 667.99. If bearish pressure persists, the price may fall to 663.33, the low bear target for the day.
Tesla Inc. (TSLA)
Tesla is trading around 390.23. Bulls will aim to push the price to 399.03. If buying momentum continues, we could see a rally to 403.43. A strong bullish trend may drive the price higher to 407.97, with the high bull target at 413.10.
If 390.23 doesn&#8217;t hold, bears will likely test support at 384.07. Continued selling could bring the price down to 378.79. If sellers remain dominant, the price may drop to the low bear target of 370.22.
Final Word: As we kick off February 2025, today&#8217;s session brings limited economic data. At 9:45 AM ET, the Final S&amp;P Global Manufacturing PMI for January will be released. Following that, at 10 AM ET, we&#8217;ll receive the ISM Manufacturing data, including Prices Paid, New Orders, and Employment figures for January. Additionally, market participants should pay attention to comments from Bostic (a non-voter) and Musalem (a voting member of the Fed), which could influence sentiment later in the day.
Market participants should remain alert to shifts in momentum as these data releases unfold, as they can spark significant volatility. Whether the market reacts strongly or remains subdued, managing risk effectively and staying disciplined will be key. Approach the day with a clear plan, adjust as needed, and trade with precision. Good luck and stay sharp!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Technicals

AAPL

Market Clubhouse Morning Memo - February 3rd, 2025 (Trade Strategy For SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META and TSLA)

Shares of U.S. automakers including Ford Motor Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) and General Motors Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) are moving lower Monday after U.S. President Donald Trump placed tariffs on <a href="https://www.benzinga.com/markets/25/02/43423288/trumps-tariffs-are-here-heres-what-will-get-more-expensive-from-canada-china-and-mexico">Canada, Mexico and China</a>.
What Happened: Trump signed executive orders on Saturday to impose 25% tariffs on Canada and Mexico and 10% tariffs on China in an effort to curb immigration and narcotics trafficking, per Reuters. 
The tariffs, which are expected to take effect on Tuesday, include a 25% duty on all&nbsp;imports from Mexico and most&nbsp;goods from Canada, as well as a 10% duty on Chinese goods. 
The auto industry is expected to be one of the hardest hit as U.S. automakers build, assemble and use parts from Canada and Mexico. Investors are also concerned about a potential trade war as Canada and Mexico have threatened to retaliate. The auto industry has a heavy reliance on North America, particularly Mexico where a lot of vehicles are manufactured.
&#8220;We may have short term some little pain, and people understand that. But long term, the United States has been ripped off by virtually every country in the world,&#8221; Trump reportedly told reporters on Sunday.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43429067/us-stocks-likely-to-open-lower-as-trump-imposes-tariffs-on-china-canada-and-mexico-expert-notes-feb-worst-month-in-post-election-years">US Stocks Likely To Open Lower As Trump Imposes Tariffs On China, Canada, And Mexico: Expert Notes Feb Worst Month In Post-Election Years</a>
General Motors reported <a href="https://www.benzinga.com/25/01/43263700/general-motors-stock-gains-after-q4-earnings-beat-incurs-charges-from-funding-halt-of-cruise-robotaxi-business">fourth-quarter earnings</a> last week that came in above analyst expectations. The automaker guided for strong earnings in 2025 on the back of growth in North America. 
Ford is due to report fourth-quarter earnings after the market close on Wednesday. The company is expected to report earnings of 33 cents per share and revenue of $43.25 billion, according to estimates from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
F, GM Price Action: Ford shares were down 3.89% at $9.68 and GM shares were down 5.90% at $46.60 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Ford.

Ford, General Motors Shares Are Sliding Monday: What's Going On?

Macro Economic Events

Econ #s

Economics

S&P Global Manufacturing PMI For January 51.2 Vs 50.1 Est.; 49.4 Prior

Republic Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) short percent of float has fallen 6.77% since its last report. The company recently reported that it has 2.53 million shares sold short, which is 1.24% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Republic Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738593959_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Republic Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Republic Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Republic Servs's peer group average for short interest as a percentage of float is 6.59%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Looking Into Republic Servs's Recent Short Interest

Cassava Sciences's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NYSE">SAVA</a>) short percent of float has fallen 7.64% since its last report. The company recently reported that it has 15.36 million shares sold short, which is 34.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 4.2 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Cassava Sciences Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738593953_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Cassava Sciences has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Cassava Sciences's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Cassava Sciences's peer group average for short interest as a percentage of float is 5.49%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

SAVA

Looking Into Cassava Sciences's Recent Short Interest

O'Reilly Automotive's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORLY#NYSE">ORLY</a>) short percent of float has fallen 18.23% since its last report. The company recently reported that it has 848 thousand shares sold short, which is 1.48% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.73 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>O'Reilly Automotive Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738593947_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for O'Reilly Automotive has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing O'Reilly Automotive's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, O'Reilly Automotive's peer group average for short interest as a percentage of float is 10.63%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

ORLY

Peering Into O'Reilly Automotive's Recent Short Interest

Deckers Outdoor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) has outperformed the market over the past 20 years by 15.82% on an annualized basis producing an average annual return of 24.14%. Currently, Deckers Outdoor has a market capitalization of $26.62 billion. 
Buying $100 In DECK: If an investor had bought $100 of DECK stock 20 years ago, it would be worth $7,649.01 today based on a price of $175.20 for DECK at the time of writing.
<h3>Deckers Outdoor's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1738593941_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

DECK

$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today

Sony Group Corporation American Depositary Shares

SONY

Sony Pictures Television Says Sony Pictures Assumed Global Distribution Functions For Wheel Of Fortune And Jeopardy!; To Begin Delivery Of Episodes Of Shows To Broadcasters Starting With Episodes Scheduled To Air The Week Of Feb 10

Scotiabank analyst Meny Grauman maintains Sun Life Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SLF#TSX">SLF</a>) with a Sector Outperform and raises the price target from C$96 to C$98.

TSX:SLF

Scotiabank Maintains Sector Outperform on Sun Life Financial, Raises Price Target to C$98

<a href="https://www.benzinga.com/markets/cryptocurrency/25/01/43218851/mark-cuban-proposes-national-debt-meme-coin-70-take-clear-side">Mark Cuban</a>'s Cost Plus Drug Company has rapidly expanded over the past year. It offers over 6,000 medicines and provides significant savings to consumers and healthcare providers alike. Cost Plus launched in 2022 and aims to lower prescription drug costs by eliminating the middleman and keeping its pricing transparent.&nbsp;
The company's <a href="https://www.benzinga.com/personal-finance/25/01/43031711/mark-cuban-was-asked-why-he-wanted-to-tackle-big-pharma-because-everybody-thinks-its-fed-up-you-know-and-theyre-right">Cost Plus Marketplace</a> debuted in February 2024, initially offering over 4,000 medicines. It offered medications that primarily were in short supply in order to directly serve healthcare facilities. Since its debut, the Marketplace has grown to offer more than 6,000 drugs, benefiting thousands of hospitals, clinics, pharmacies, and other medical facilities across all 50 states.&nbsp;
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>
The company's chief commercial officer, Alan Bowe, told Becker's Hospital Review that customers have saved between 40% and 60%, compared with traditional wholesalers.&nbsp;
Several major healthcare organizations have begun purchasing from Cost Plus, including MultiCare Health System in Tacoma, Washington, ScionHealth in Louisville, Kentucky, and Community Health Systems in Franklin, Tennessee. According to Becker's Hospital Review, MultiCare alone saved $1.12 million in just seven months after purchasing 125 generic medications at discounted rates.&nbsp;
Cost Plus was founded on the principle of making <a href="https://www.benzinga.com/24/12/42270592/pharma-pushes-to-revise-medicare-drug-price-negotiation-law-under-trump-administration">prescription medications more affordable</a>. In the company's mission statement, Cuban wrote, "We started Mark Cuban Cost Plus Drug Company because every American should have access to safe, affordable medicines…No American should have to suffer–or worse–because they can't afford basic prescription medications."
Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks">this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</a>
In the company's mission statement, Cuban emphasized the need for transparent drug pricing and how customers should know exactly how those costs are calculated. The company's pricing model is simple: the cost of the drug plus a 15% markup and any applicable pharmacy fees.&nbsp;
One example of the company's impact is its pricing for Albendazole, a drug used to treat parasitic infections. Traditional pricing for the drug can reach $500 per treatment. Cost Plus offers it for $35, including pharmacy fees. Its cost for the drug is $26.08. The 15% markup brings it to about $30. Their pharmacy partners charge $5 to prepare and distribute the drug, bringing it to its cost of $35.
See Also: The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?
Most insurers and employers contract with <a href="https://www.benzinga.com/24/12/42554729/pharmacy-benefit-managers-played-key-role-in-worsening-opioid-crisis-drug-makers-paid-staggering-rebates-to-the-middlemen">pharmacy benefit managers</a> to negotiate and manage prescription drug benefits. This leads to confusing costs and lack of transparency.&nbsp;
Cost Plus cuts the PBMs out of the equation and allows hospitals and clinics to redirect savings to other critical areas, like patient care and operational improvements.&nbsp;
Cuban plans to expand the Marketplace this year by adding more brand-name medications and biosimilars. As more people and companies start using this alternative for their prescription drugs, it could set a new standard for <a href="https://www.benzinga.com/general/biotech/25/01/43065450/teva-challenges-drug-price-laws-impact-on-innovation-generics">drug pricing</a> in the future and further disrupt the industry at large.&nbsp;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a></li>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
</ul>

Personal Finance

Mark Cuban's Cost Plus Marketplace Now Sells Over 6,000 Medicines, Saving Customers Between 40-60% By Cutting Out The Middle Man

RBC Capital analyst Kenneth Lee maintains Artisan Partners Asset (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APAM#NYSE">APAM</a>) with a Outperform and lowers the price target from $53 to $51.

APAM

RBC Capital Maintains Outperform on Artisan Partners Asset, Lowers Price Target to $51

Scotiabank analyst Meny Grauman maintains Manulife Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/MFC#TSX">MFC</a>) with a Sector Outperform and raises the price target from C$49 to C$53.

TSX:MFC

Scotiabank Maintains Sector Outperform on Manulife Financial, Raises Price Target to C$53

Scotiabank analyst Meny Grauman downgrades iA Financial (TSX:<a class="ticker" href="https://www.benzinga.com/stock/IAG#TSX">IAG</a>) from Sector Outperform to Sector Perform and announces C$143 price target.

Downgrades

TSX:IAG

Scotiabank Downgrades iA Financial to Sector Perform, Announces C$143 Price Target

Contracts

NCR Voyix Awarded $335M Contract With Defense Commissary Agency For DeCA Enterprise Business Operations Solutions

Lilly tops Morgan Stanley's biopharma pick list for 2025

Here are Morgan Stanley's key oncology catalysts for 2025

Arcus: Excellent Pipeline And Collaborations, Cash Runway

Arcus Biosciences: Many Important Oncology Catalysts Coming Up In 2025

In a report released today, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – Research Report), ...

Bank of America Securities Keeps Their Hold Rating on Arcus Biosciences (RCUS)

Barclays analyst Peter Lawson maintained a Buy rating on Arcus Biosciences (RCUS – Research Report) today and set a price target of $29.00. The com...

Barclays Keeps Their Buy Rating on Arcus Biosciences (RCUS)

Undercovered Dozen: Lincoln National, Whitecap Resources, NMI Holdings, Healwell AI +

Arcus Biosciences (RCUS) announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer effective January 31, 2025. Dr. Marku...

Arcus Biosciences names Richard Markus chief medical officer

The latest update is out from Arcus Biosciences ( ($RCUS) ). Arcus Biosciences, Inc. announced on January 21, 2025, that Dr. Richard Markus will be...

Arcus Biosciences Announces New Chief Medical Officer

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cigna (CI – Research Report), Vertex Pharmaceuticals (VRTX – Rese...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Vertex Pharmaceuticals (VRTX) and Arcus Biosciences (RCUS)

ABBV

AKESF

ALMS

APPTF

ARVN

BAYRY

BAYZF

BHVN

BIZD

BNTX

DSKYF

DSNKY

GILD

GPCR

HWAIF

MRNA

NMIH

NTLA

PFLT

RCUS

REGN

RHHBF

RHHBY

RHHVF

RPRX

SMMT

SPGYF

SRPT

TGTX

UPST

VRTX

Press Releases

Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

Arcus Biosciences Announces New Employment Inducement Grants

Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Small Cap

Opinion

Biotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

Arcus Biosciences to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Comments

Arcus Biosciences

Interés en corto

Arcus Biosciences (NYSE:RCUS) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL